(Q36467852)

14 August 2017

In vitro evaluation of the potential of aclarubicin in the treatment of small cell carcinoma of the lung (SCCL). (English)

1 reference

14 August 2017

0 references

1 reference

Jensen PB

1

1 reference

14 August 2017

Vindeløv L

2

1 reference

14 August 2017

Roed H

3

1 reference

14 August 2017

Demant EJ

4

1 reference

14 August 2017

Sehested M

5

1 reference

14 August 2017

Skovsgaard T

6

1 reference

14 August 2017

Hansen HH

7

1 reference

14 August 2017

language of work or name

English

0 references

publication date

1 December 1989

1 reference

British Journal of Cancer

14 August 2017

1 reference

14 August 2017

60

1 reference

14 August 2017

838-844

1 reference

14 August 2017

6

1 reference

describes a project that uses

14 August 2017

0 references

0 references

0 references

0 references

0 references

0 references

0 references

https://scigraph.springernature.com/pub.10.1038/bjc.1989.376

0 references

cites work

Phase I--II evaluation of a new anthracycline antibiotic, aclacinomycin A, in adults with refractory leukemia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2247271

Aclarubicin in the treatment of acute nonlymphocytic leukemia refractory to treatment with daunorubicin and cytarabine: a phase II trial

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2247271

A Detergent-trypsin method for the preparation of nuclei for flow cytometric DNA analysis

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2247271

9-alkyl anthracyclines. Absence of cross-resistance to adriamycin in human and murine cell cultures

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2247271

Pharmacodynamic aspects of aclarubicin with special reference to daunorubicin and doxorubicin.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2247271

Derivation and preliminary characterisation of adriamycin resistant lines of human lung cancer cells

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2247271

Mechanism of multidrug resistance

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2247271

Stability of solutions of antineoplastic agents during preparation and storage for in vitro assays. II. Assay methods, adriamycin and the other antitumour antibiotics

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2247271

Development and cross-resistance characteristics of a subline of P388 leukemia resistant to 4'-(9-acridinylamino)-methanesulfon-m-anisidide.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2247271

Identification of anthracycline analogues with enhanced cytotoxicity and lack of cross-resistance to adriamycin using a series of mammalian cell lines in vitro.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2247271

Phase II study of aclarubicin and diaziquone in the treatment of advanced small cell bronchogenic carcinoma (EST 4581): an Eastern Cooperative Oncology Group Study.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2247271

Characterization of three new variant type cell lines derived from small cell carcinoma of the lung.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2247271

Establishment and identification of small cell lung cancer cell lines having classic and variant features.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2247271

Inter-experiment variation and dependence on culture conditions in assaying the chemosensitivity of human small cell lung cancer cell lines.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2247271

Experimental studies of new anthracyclines: aclacinomycin, THP-adriamycin and ditrisarubicins.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2247271

Detection of P-glycoprotein in multidrug-resistant cell lines by monoclonal antibodies

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2247271

Drug sensitivity of an adriamycin-resistant mutant subline of mouse lymphoblastoma L5178Y cells.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2247271

Phase I-II study of aclarubicin for treatment of acute myeloid leukemia.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2247271

New antitumor antibiotics, aclacinomycins A and B

21 September 2018

1 reference

12 December 2020

Comparative effectiveness of mitoxantrone and doxorubicin in overcoming experimentally induced drug resistance in murine and human tumour cell lines in vitro

1 reference

12 December 2020

New anthracycline antibiotic aclacinomycin A: experimental studies and correlations with clinical trials

1 reference

12 December 2020

A phase I clinical trial of aclacinomycin A administered on a five-consecutive-day schedule

1 reference

12 December 2020

Intermittent high-dose aclarubicin in patients with advanced cancer: a phase I study with special reference to cardiac toxicity

1 reference

12 December 2020

Long-term storage of samples for flow cytometric DNA analysis

1 reference

12 December 2020

Phase II evaluation of aclarubicin in lung cancer: a Southeastern Cancer Study Group Trial

1 reference

12 December 2020

Phase I-II trial of aclacinomycin A given in a four-consecutive-day schedule to patients with solid tumours. A South-East European Oncology Group (SEEOG) Study

1 reference

12 December 2020

Identifiers

DOI

10.1038/BJC.1989.376

1 reference

14 August 2017

1 reference

14 August 2017

1 reference